TNFSF11 and diabetes mellitus: With the discovery of the negative impact of RANKL on glucose metabolism [25,26,27,28,29,30], mechanistic and clinical studies elaborating on the effects of denosumab on plasma glucose and diabetes development are on the rise, although the evidence is not quite conclusive.